Boundless Bio, a precision oncology company, announced the closing of an oversubscribed $105 Million Series B financing.

Boundless Bio is a biotechnology company focused on interrogating a novel area of cancer biology, extrachromosomal DNA (ecDNA), to deliver transformative therapies to patients with previously intractable cancers.

RA Capital Management and Nextech Invest co-led the financing, with participation from a top-tier syndicate of funds, including Fidelity Management & Research Company, Redmile Group, Wellington Management, Surveyor Capital (a Citadel company), PFM Health Sciences, and Logos Capital.

Current investors ARCH Venture Partners, City Hill Ventures, Vertex Ventures HC, GT Healthcare Capital Partners, Boxer Capital of Tavistock Group, and Alexandria Venture Investments also participated in the Series B.